Search results for " drug therapy"

showing 10 items of 95 documents

Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection.

2007

Summary.  Hepatitis C virus (HCV) infection is associated with a significant reduction of health related quality of life (QOL), the causes and mechanisms of which are still unknown. To explore whether treatment history could affect QOL, we examined patients with detectable HCV viraemia who had a different therapeutic background. Two hundred sixty-four consecutive subjects with chronic HCV infection and detectable viraemia were enrolled. Of these, 163 were untreated patients, 43 were relapsers, 58 were nonresponders (NR) to nonpegylated interferon (IFN) therapy. To assess QOL, three self-report instruments were employed: the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLD…

AdultMaleQuestionnairesmedicine.medical_specialtyHealth StatusHepatitis C virusComorbidityAffect (psychology)Chronic liver diseasemedicine.disease_causeliver-specific quality of life nonresponse to treatment physical comorbidity quality of lifeWorld healthVirusQUALITY OF LIFEChronic hepatitisQuality of lifeSurveys and QuestionnairesVirologyInternal medicineHumansMedicineChronicAgedHepatologybusiness.industryHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CComorbidityhumanitiesAdult Aged Comorbidity Female Health Status Hepatitis C; Chronic; drug therapy/virology Humans Interferons; therapeutic use Linear Models Male Middle Aged Quality of Life Questionnairesdrug therapy/virologyInfectious Diseasestherapeutic useHCVLinear ModelsPhysical therapyFemaleInterferonsbusiness
researchProduct

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

2007

Summary Background Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentLipoproteinsAmphotericin B/ therapeutic useMicrobial Sensitivity TestsLipoproteins/ therapeutic usePeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BPeptides Cyclic/ therapeutic usemedicineHumansAdverse effectMycosisFungemiaCandidiasis/complications/ drug therapy/microbiologyAPACHEAgedddc:616Aged 80 and overVoriconazolebusiness.industryAntifungal Agents/ therapeutic useCandidiasisMicafunginGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseApacheSurgeryTreatment OutcomechemistryMicafunginFemaleCaspofunginbusinessFluconazolemedicine.drugThe Lancet
researchProduct

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Lipoprotein(a) and aortic valve stenosis: A casual or causal association?

2022

Abstract Aims This review aims to provide an update of available methods for imaging calcification activity and potential therapeutic options. Data Synthesis: Aortic valve calcification represents the most common heart valve condition requiring treatment among adults in Western societies. No medical therapies are proven to be effective in treating symptoms or reducing disease progression. Therefore, surgical or transcatheter aortic valve replacement remains the only available treatment option. Elevated circulating concentrations of lipoprotein(a) is strongly associated with degenerative aortic stenosis. This relationship was first observed in prospective observational studies, and the causa…

Adultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedicine (miscellaneous)Settore MED/11 - Malattie dell'Apparato CardiovascolareAortic valve stenosisAortic valve calcification; Aortic valve stenosis; Drug therapy; Lipoprotein (a)Valve replacementLipoprotein (a)Internal medicinemedicineHumansProspective StudiesHeart valveNutrition and Dieteticsbiologybusiness.industryCalcinosisLipoprotein(a)medicine.diseaseObservational Studies as TopicStenosismedicine.anatomical_structureAortic ValveAortic valve stenosisAortic valve calcificationbiology.proteinCardiologyObservational studyDrug therapyAortic valve calcificationCardiology and Cardiovascular MedicinebusinessLipoprotein(a)CalcificationNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Low dosage liposomal amphotericin B in the treatment of Candida infections in critically ill patients.

2011

Antifungal AgentsTreatment OutcomeCritical care candida sepsisAmphotericin BCritical IllnessCandidiasisHumansSettore MED/41 - AnestesiologiaPilot ProjectsAmphotericin B; administration /&/ dosage Antifungal Agents; administration /&/ dosage Candidiasis; drug therapy Critical Illness Humans Middle Aged Pilot Projects Treatment OutcomeMiddle Agedadministration /&/ dosagedrug therapy
researchProduct

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST).

2022

BACKGROUND: The management of epilepsy in older adults has become part of daily practice because of an aging population. Older patients with epilepsy represent a distinct and more vulnerable clinical group as compared with younger patients, and they are generally under-represented in randomized placebo-controlled trials. Real-world studies can therefore be a useful complement to characterize the drug's profile. Brivaracetam is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A and approved as adjunctive therapy for focal seizures in adults with epilepsy. OBJECTIVE: The aim of this study was to assess the 12-month effectiveness and tolerabil…

Antiseizure medicationEpilepsySettore MED/26PyrrolidinonesFocal seizuresTreatment OutcomeDrug TherapyDouble-Blind MethodItalySeizuresBrivaracetamCombinationAntiseizure medication; Brivaracetam; Focal seizuresAged; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Anticonvulsants; EpilepsyHumansPharmacology (medical)Settore MED/26 - NeurologiaAnticonvulsantsDrug Therapy CombinationGeriatrics and GerontologyAgedRetrospective StudiesDrugsaging
researchProduct

The HCV Sicily Network: A web-based model for the management of HCV chronic liver diseases

2016

Epidemiological studies report that in Sicily reside about 30,000 citizens with a diagnosis of chronic hepatitis due to HCV. The availability of direct antiviral action (DAA) is a real therapeutic breakthrough, but the high cost of the therapeutic regimes limits their use and forced the National Health System to establish clinical priority for the treatment.The HCV Sicily Network is a web-based model of best medical practice, which was designed to improve the management and the treatment of HCV chronic hepatitis and cirrhosis. The network includes 41 centers and 84 gastroenterologists or infectivologists connected by a web platform that recorder the diagnosis and the clinic priority for the…

Antiviral AgentMaleInternetHepaciviruHepatitis C virusInterferon-alphaDirect antiviral agent drugs (DAA); Hepatitis C virus; Web-based network; Pharmacology (medical)HepacivirusHepatitis C ChronicMiddle AgedWeb-based network; Hepatitis C virus; Direct antiviral agent drugs (DAAAntiviral AgentsCommunity NetworksTreatment OutcomeAntiviral Agents; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Internet; Male; Middle Aged; Ribavirin; Sicily; Treatment Outcome; Community NetworksRibavirinHumansDirect antiviral agent drugs (DAADrug Therapy CombinationSicilyWeb-based networkHuman
researchProduct

Artificial intelligence techniques for cancer treatment planning

1988

An artificial intelligence system, NEWCHEM, for the development of new oncology therapies is described. This system takes into account the most recent advances in molecular and cellular biology and in cell-drug interaction, and aims to guide experimentation in the design of new optimal protocols. Further work is being carried out, aimed to embody in the system all the basic knowledge of biology, physiopathology and pharmacology, to reason qualitatively from first principles so as to be able to suggest cancer therapies.

Artificial Intelligence SystemKnowledge representation and reasoningbusiness.industryAnimals Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage/pharmacology Clinical Protocols Computer Simulation Drug Therapy; Computer-Assisted Expert Systems Humans Medical Oncology; methods Programming Languages Software Design Therapy; Computer-AssistedExpert SystemsMedical OncologyDrug Therapy Computer-AssistedmethodsCancer treatmentComputer-AssistedBasic knowledgeadministration /&/ dosage/pharmacologyClinical ProtocolsDrug TherapySoftware DesignTherapy Computer-AssistedAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansComputer SimulationProgramming LanguagesTherapyArtificial intelligenceAutomated reasoningbusinessMedical Informatics
researchProduct

Neurobiologia e terapia dei disturbi della sfera affettiva nell'autismo: conoscenze attuali

2007

L’autismo è un disordine dello sviluppo del cervello che insorge in periodo perinatale ed è caratterizzato da disturbi del comportamento sociale, da difficoltà nelle interazioni con gli altri, da deficit del linguaggio, dalla presenza di atteggiamenti di tipo ripetitivo ed ossessivo, da alterazioni della sfera affettiva ed emozionale. L’incidenza dell’autismo ha ormai assunto le dimensioni di una vera e propria epidemia, per cui è prioritario avere a disposizione terapie realmente efficaci. Purtroppo attualmente non esiste alcun trattamento farmacologico che non sia puramente sintomatico. La carenza di farmaci efficaci è dovuto al fatto che i meccanismi neurobiologici alla base dell’autismo…

Autism neurobiological mechanism drug therapy
researchProduct

Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in I…

2021

Background: Information on the management of Helicobacter (H.) pylori infection by gastroenterologists and gastroenterology fellows are scarce. We aimed to assess practice of gastroenterologists and gastroenterology fellows and their adherence to guidelines for diagnosis and treatment of H. pylori infection in Italy. Materials and Methods: All gastroenterologists and gastroenterology fellows attending the National Congress of Digestive Diseases - FISMAD were invited to fill-in an on-line questionnaire. The questionnaire included questions on the diagnosis and treatment of H. pylori infection. Results: A total of 279 gastroenterologists and 61 gastroenterology fellows participated to the stu…

Background informationHelicobacter pylori infectionmedicine.medical_specialtygenetic structuresdiagnosisgastroenterology fellowGastroenterologyHelicobacter pylori; diagnosis; gastroenterologists; gastroenterology fellows; guidelines; treatment; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy Combination; Humans; Proton Pump Inhibitors; Surveys and Questionnaires; Gastroenterologists; Gastroenterology; Helicobacter Infections; Helicobacter pyloriHelicobacter InfectionsDrug TherapyClarithromycinInternal medicineClarithromycinSurveys and QuestionnairesMedicineHumansguidelinesbiologyHelicobacter pyloritreatmentbusiness.industryGastroenterologistsGastroenterologyAmoxicillinProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationeye diseasesAnti-Bacterial AgentsdiagnosiInfectious Diseasesgastroenterology fellowsThird lineCombinationDrug Therapy CombinationgastroenterologistEducational interventionsbusinessguidelineBismuthmedicine.drug
researchProduct